WO2003000269A3 - Nouvelle utilisation d'inhibiteurs de pde 10a - Google Patents

Nouvelle utilisation d'inhibiteurs de pde 10a

Info

Publication number
WO2003000269A3
WO2003000269A3 PCT/EP2002/006309 EP0206309W WO03000269A3 WO 2003000269 A3 WO2003000269 A3 WO 2003000269A3 EP 0206309 W EP0206309 W EP 0206309W WO 03000269 A3 WO03000269 A3 WO 03000269A3
Authority
WO
WIPO (PCT)
Prior art keywords
pde
inhibitors
novel use
prophylaxis
medicament
Prior art date
Application number
PCT/EP2002/006309
Other languages
German (de)
English (en)
Other versions
WO2003000269A2 (fr
Inventor
Ulrich Niewoehner
Jens-Kerim Ergueden
Marcus Bauser
Nils Burkhardt
Dietmar Flubacher
Arno Friedl
Irene Gerlach
Volker Hinz
Reinhard Jork
Paul Naab
Thorsten-Oliver Repp
Karl-Heinz Schlemmer
Juergen Stoltefuss
Original Assignee
Bayer Ag
Ulrich Niewoehner
Jens-Kerim Ergueden
Marcus Bauser
Nils Burkhardt
Dietmar Flubacher
Arno Friedl
Irene Gerlach
Volker Hinz
Reinhard Jork
Paul Naab
Thorsten-Oliver Repp
Karl-Heinz Schlemmer
Juergen Stoltefuss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Ulrich Niewoehner, Jens-Kerim Ergueden, Marcus Bauser, Nils Burkhardt, Dietmar Flubacher, Arno Friedl, Irene Gerlach, Volker Hinz, Reinhard Jork, Paul Naab, Thorsten-Oliver Repp, Karl-Heinz Schlemmer, Juergen Stoltefuss filed Critical Bayer Ag
Publication of WO2003000269A2 publication Critical patent/WO2003000269A2/fr
Publication of WO2003000269A3 publication Critical patent/WO2003000269A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
    • F17C2201/00—Vessel construction, in particular geometry, arrangement or size
    • F17C2201/01—Shape
    • F17C2201/0104—Shape cylindrical
    • F17C2201/0119—Shape cylindrical with flat end-piece
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
    • F17C2201/00—Vessel construction, in particular geometry, arrangement or size
    • F17C2201/05—Size
    • F17C2201/058—Size portable (<30 l)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
    • F17C2203/00—Vessel construction, in particular walls or details thereof
    • F17C2203/06—Materials for walls or layers thereof; Properties or structures of walls or their materials
    • F17C2203/0602—Wall structures; Special features thereof
    • F17C2203/0612—Wall structures
    • F17C2203/0614—Single wall
    • F17C2203/0617—Single wall with one layer
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
    • F17C2203/00—Vessel construction, in particular walls or details thereof
    • F17C2203/06—Materials for walls or layers thereof; Properties or structures of walls or their materials
    • F17C2203/0634—Materials for walls or layers thereof
    • F17C2203/0636—Metals
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
    • F17C2205/00—Vessel construction, in particular mounting arrangements, attachments or identifications means
    • F17C2205/03—Fluid connections, filters, valves, closure means or other attachments
    • F17C2205/0302—Fittings, valves, filters, or components in connection with the gas storage device
    • F17C2205/0311—Closure means
    • F17C2205/0314—Closure means breakable, e.g. with burst discs
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
    • F17C2209/00—Vessel construction, in particular methods of manufacturing
    • F17C2209/22—Assembling processes
    • F17C2209/221—Welding
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
    • F17C2209/00—Vessel construction, in particular methods of manufacturing
    • F17C2209/22—Assembling processes
    • F17C2209/228—Assembling processes by screws, bolts or rivets
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
    • F17C2223/00—Handled fluid before transfer, i.e. state of fluid when stored in the vessel or before transfer from the vessel
    • F17C2223/01—Handled fluid before transfer, i.e. state of fluid when stored in the vessel or before transfer from the vessel characterised by the phase
    • F17C2223/0107—Single phase
    • F17C2223/0123—Single phase gaseous, e.g. CNG, GNC
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
    • F17C2260/00—Purposes of gas storage and gas handling
    • F17C2260/02—Improving properties related to fluid or fluid transfer
    • F17C2260/021—Avoiding over pressurising
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F17—STORING OR DISTRIBUTING GASES OR LIQUIDS
    • F17C—VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES
    • F17C2270/00—Applications
    • F17C2270/01—Applications for fluid transport or storage
    • F17C2270/0165—Applications for fluid transport or storage on the road
    • F17C2270/0181—Airbags

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation d'inhibiteurs de PDE 10A pour produire un médicament servant à traiter et/ou à prévenir des maladies neurodégénératives, telles que la maladie de Parkinson.
PCT/EP2002/006309 2001-06-22 2002-06-10 Nouvelle utilisation d'inhibiteurs de pde 10a WO2003000269A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10130151.0 2001-06-22
DE10130151A DE10130151A1 (de) 2001-06-22 2001-06-22 Neue Verwendung für PDE 10A-Inhibitoren

Publications (2)

Publication Number Publication Date
WO2003000269A2 WO2003000269A2 (fr) 2003-01-03
WO2003000269A3 true WO2003000269A3 (fr) 2003-04-03

Family

ID=7689081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006309 WO2003000269A2 (fr) 2001-06-22 2002-06-10 Nouvelle utilisation d'inhibiteurs de pde 10a

Country Status (2)

Country Link
DE (1) DE10130151A1 (fr)
WO (1) WO2003000269A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
MXPA05013822A (es) * 2003-06-30 2006-02-28 Altana Pharma Ag Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer.
AU2005323794B2 (en) * 2005-01-07 2012-07-19 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as PDE10 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457671A2 (fr) * 1990-05-14 1991-11-21 FIDIA S.p.A. Dipyridamide pour le traitement du système nerveux central ou périphérique
WO1995019173A1 (fr) * 1994-01-14 1995-07-20 EGIS Gyógyszergyár Rt. Compositions pharmaceutiques
WO2001024781A2 (fr) * 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessaire a la fonction striatale, ses applications et composes permettant de moduler ce gene
EP1250923A2 (fr) * 2001-04-20 2002-10-23 Pfizer Products Inc. Utilisation des inhibiteurs sélectifs de PDE10 pour le traitement des maladies du système nerveux central

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0457671A2 (fr) * 1990-05-14 1991-11-21 FIDIA S.p.A. Dipyridamide pour le traitement du système nerveux central ou périphérique
WO1995019173A1 (fr) * 1994-01-14 1995-07-20 EGIS Gyógyszergyár Rt. Compositions pharmaceutiques
WO2001024781A2 (fr) * 1999-10-07 2001-04-12 Novaneuron Inc. Gene necessaire a la fonction striatale, ses applications et composes permettant de moduler ce gene
EP1250923A2 (fr) * 2001-04-20 2002-10-23 Pfizer Products Inc. Utilisation des inhibiteurs sélectifs de PDE10 pour le traitement des maladies du système nerveux central

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, SEEGER T F ET AL: "PDE10A mRNA in situ hybridization mapping in the rodent brain: apparent co-localization with dopaminoceptive neurons.", XP002219920, Database accession no. PREV200100096813 *
KOTOMI FUJISHIGE ET AL: "Cloning and Characterization of a Novel Human Phosphodiesterase that hydrolyses both cAMP and cGMP (PDE10A)", JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS), AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 26, 25 June 1999 (1999-06-25), pages 18438 - 18445, XP002197149 *
LOUGHNEY K ET AL: "Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 234, no. 1, 24 June 1999 (1999-06-24), pages 109 - 117, XP004176895, ISSN: 0378-1119 *
MONTOLIU CARMINA ET AL: "Role of cyclic GMP in glutamate neurotoxicity in primary cultures of cerebellar neurons.", NEUROPHARMACOLOGY, vol. 38, no. 12, December 1999 (1999-12-01), pages 1883 - 1891, XP002219921, ISSN: 0028-3908 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000, pages Abstract No. - 345.10, ISSN: 0190-5295 *
SODERLING ET AL: "Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, 8 June 1999 (1999-06-08), pages 7071 - 7076, XP002139277, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2003000269A2 (fr) 2003-01-03
DE10130151A1 (de) 2003-01-02

Similar Documents

Publication Publication Date Title
WO2003080582A3 (fr) Derives de fredericamycine
DOP2002000429A (es) Imidazotriazinas
WO2004014953A3 (fr) Anticorps
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
ZA200306234B (en) Phenethanolamine derivatives for treatment of respiratory diseases.
WO2004006858A3 (fr) Composes, compositions et methodes d&#39;utilisation de ces derniers
CA2458067A1 (fr) Utilisation de la flibanserine dans le traitement de troubles sexuels
WO2002069945A3 (fr) Nouvelles preparations de medicaments a base d&#39;anticholinergiques et d&#39;inhibiteurs pde-iv
ZA200604114B (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson&#39;s disease
HK1128679A1 (en) 1,2-diphenylethene derivatives for treatment of immune diseases 12-
WO2001098279A3 (fr) Bis-arylsulfones
WO2003039539A3 (fr) Utilisation d&#39;antagonistes du recepteur de l&#39;endotheline dans le traitement de maladies tumorales
AU2002312897A1 (en) Drugs for the treatment of the alzheimer disease
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2003037863A3 (fr) Indoles substitues, procede pour leur preparation et leur utilisation pour lutter contre la douleur
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
WO2003000269A3 (fr) Nouvelle utilisation d&#39;inhibiteurs de pde 10a
AU2003303217A1 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
WO2003024996A3 (fr) Macrocycles antibacteriens
WO2002069944A3 (fr) Nouvelles compositions medicamenteuses a base d&#39;anticholinergiques et d&#39;antagonistes de recepteurs nk1
WO2005047278A3 (fr) Dihydroquinazolines ii substituees
WO2002074034A3 (fr) Nouvelles compositions medicamenteuses a base d&#39;anticholinergiques et d&#39;antagonistes de l&#39;endotheline
EA200100876A3 (ru) Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW GH GM KE LS MW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP